The global “immunomodulators market” is set to gain momentum from the increasing research activities to introduce unique approaches to treat cancer effectively. This information is published by Fortune Business Insights™ in a new study, titled, “Immunomodulators Market Size, Share & Industry Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027.” The study further mentions that the immunomodulators market size was USD 161.57 billion in 2019. It is projected to grow from USD 186.12 billion in 2020 to USD 285.01 billion in 2027 at a CAGR of 6.3% during the forecast period.
Get Request a Sample Copy of the Immunomodulators Report:
https://www.fortunebusinessinsights.com/enquiry/sample/immunomodulators-market-104692
Major Immunomodulators Market Key players covered in the report include:
- Hoffmann-La Roche Ltd (Basel, Switzerland)
- Novartis AG (Basel, Switzerland)
- Biogen (Massachusetts, U.S.)
- Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
- Amgen, Inc (California, U.S.)
- Bristol-Myers & Squibb Company (New York, U.S)
- Merck Sharp & Dohme Corp. (New jersey, U.S)
- Eli Lilly and Company (Indiana, U.S)
- Other Players
Immunomodulators Market Analysis 2021:
Drivers & Restraints-
Rising Cases of Rheumatoid Arthritis to Accelerate Growth
The higher prevalence of multiple sclerosis is considered to be the second major cause of death, followed by cardiovascular disorders. The rising number of ongoing clinical trials to develop immunotherapeutic agents, namely, laquinimod, ozanimod, and ponesimod would propel the immunomodulators market in the upcoming years. Apart from that, the rising need to treat autoimmune disorders, such as rheumatoid arthritis is anticipated to spur demand. However, immunomodulators can cause severe infections including HIB, TB, fungal infections, hepatitis B, and hepatitis C viruses. These factors may hinder the demand for such drugs.
Segment-
Immunosuppressant Segment Held Highest Share Fueled by Rising Availability of Drugs
Based on the product type, the immunosuppressant segment held the majority of the immunomodulators market share in 2019. This growth is attributable to the usage of these drugs for treating autoimmune disorders, such as lupus and alopecia areata. Also, the presence of a wide range of these drugs capable of effectively treating the above-mentioned diseases would boost growth of the segment.
Investment in Quality Control to Favor Growth amid COVID-19 Pandemic
The COVID-19 pandemic is set to affect the market for immunomodulators positively in the near future backed by the increasing sales of these products. Besides, numerous pharmaceutical companies are aiming to maintain the balance between demand and supply to keep their sales intact. They are also trying to invest more in quality control, refine their R&D activities, and enhance the supply chain management. We are offering in-depth analysis of the market to help you invest in the right zones.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/immunomodulators-market-104692
Regional Insights-
Increasing Prevalence of Chronic Diseases to Drive Growth in North America
Geographically, in 2019, North America procured USD 61.91 billion in terms of revenue. The region is expected to retain its dominant position throughout the forthcoming years on account of the surging incidence of chronic diseases in the U.S. Europe, on the other hand, is set to remain in the second position backed by the increasing sales of immunosuppressant products in the region. In Asia Pacific, would show the highest CAGR stoked by the rising number of ongoing studies associated with immunomodulators. Also, the increasing geriatric population would intensify demand in the region.
Competitive Landscape-
Key Players Focus on Introducing State-of-the-art Drugs to Gain a Competitive Edge
The global market for immunomodulators contains a large number of big, small, and medium companies. Most of them are striving persistently to gain a competitive edge in the market. To do so, they are coming up with novel immunomodulators to treat various chronic diseases. Below are the two latest industry developments:
- October 2020: Cytocom, Inc. and Cleveland BioLabs, Inc. signed a merger agreement to blend their businesses in an individual transaction. This merger will transform the growth opportunity for Cleveland and Cytocom shareholders. It will also strengthen their positions and accelerate their potential to treat serious medical conditions with immune-modulating agents.
- January 2020: Bristol Myers Squibb introduced its latest drug named Zeposia to treat multiple sclerosis. It can not only address less recognized cognitive issues but also the physical aspects of multiple sclerosis.
Have Any Query? Ask Our Experts:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunomodulators-market-104692
Table of Content:
1 Immunomodulators Market Overview
1.1 Immunomodulators Product Overview
1.2 Immunomodulators Market Segment by Type
1.3 Global Immunomodulators Market Size by Type (2015-2027)
1.3.1 Global Immunomodulators Market Size Overview by Type (2015-2027)
1.3.2 Global Immunomodulators Historic Market Size Review by Type (2015-2021)
1.3.2.1 Global Immunomodulators Sales Market Share Breakdown by Type (2015-2027)
1.3.2.2 Global Immunomodulators Market Share Breakdown by Type (2015-2027)
1.3.2.3 Global Immunomodulators Average Selling Price (ASP) by Type (2015-2027)
1.3.3 Global Immunomodulators Market Size Forecast by Type (2021-2027)
1.3.3.1 Global Immunomodulators Sales Market Share Breakdown by Application (2021-2027)
1.3.3.2 Global Immunomodulators Revenue Market Share Breakdown by Application (2021-2027)
1.3.3.3 Global Immunomodulators Average Selling Price (ASP) by Application (2021-2027)
1.4 Key Regions Market Size Segment by Type (2015-2021)
1.4.1 North America Immunomodulators Sales Breakdown by Type (2015-2027)
1.4.2 Europe Immunomodulators Sales Breakdown by Type (2015-2027)
1.4.3 Asia-Pacific Immunomodulators Sales Breakdown by Type (2015-2027)
1.4.4 Latin America Immunomodulators Sales Breakdown by Type (2015-2027)
1.4.5 Middle East and Africa Immunomodulators Sales Breakdown by Type (2015-2027)
2 Global Immunomodulators Market Competition by Company
2.1 Global Top Players by Immunomodulators Sales (2015-2021)
2.2 Global Top Players by Immunomodulators Revenue (2015-2021)
2.3 Global Top Players Immunomodulators Average Selling Price (ASP) (2015-2021)
2.4 Global Top Company Immunomodulators Manufacturing Base Distribution, Sales Area, Product Type
2.5 Immunomodulators Market Competitive Situation and Trends
2.5.1 Immunomodulators Market Growth Rate (2015-2021)
2.5.2 Global 5 and 10 Largest Company by Immunomodulators Sales and Revenue in 2019
2.6 Global Top Company by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immunomodulators as of 2019)
2.7 Date of Key Company Enter into Immunomodulators Market
2.8 Key Company Immunomodulators Product Offered
2.9 Mergers and Acquisitions, Expansion
3 Global Immunomodulators Status and Outlook by Region (2015-2027)
3.1 Global Immunomodulators Market Size and CAGR by Region: 2015 VS 2021 VS 2027
3.2 Global Immunomodulators Market Size Market Share by Region (2015-2021)
3.2.1 Global Immunomodulators Sales Market Share by Region (2015-2021)
3.2.2 Global Immunomodulators Revenue Market Share by Region (2015-2021)
3.2.3 Global Immunomodulators Sales, Revenue, Price and Gross Margin (2015-2021)
3.3 Global Immunomodulators Market Size Market Share by Region (2021-2027)
3.3.1 Global Immunomodulators Sales Market Share by Region (2021-2027)
3.3.2 Global Immunomodulators Revenue Market Share by Region (2021-2027)
3.3.3 Global Immunomodulators Sales, Revenue, Price and Gross Margin (2021-2027)
3.4 North America Immunomodulators Market Size By Growth (2015-2027)
3.4.1 North America Immunomodulators Revenue By Growth (2015-2027)
3.4.2 North America Immunomodulators Sales By Growth (2015-2027)
3.5 Asia-Pacific Immunomodulators Market Size By Growth (2015-2027)
3.5.1 Asia-Pacific Immunomodulators Revenue By Growth (2015-2027)
3.5.2 Asia-Pacific Immunomodulators Sales By Growth (2015-2027)
3.6 Europe Immunomodulators Market Size By Growth (2015-2027)
3.6.1 Europe Immunomodulators Revenue By Growth (2015-2027)
3.6.2 Europe Immunomodulators Sales By Growth (2015-2027)
3.7 Latin America Immunomodulators Market Size By Growth (2015-2027)
3.7.1 Latin America Immunomodulators Revenue By Growth (2015-2027)
3.7.2 Latin America Immunomodulators Sales By Growth (2015-2027)
3.8 Middle East and Africa Immunomodulators Market Size By Growth (2015-2027)
3.8.1 Middle East and Africa Immunomodulators Revenue By Growth (2015-2027)
3.8.2 Middle East and Africa Immunomodulators Sales By Growth (2015-2027)
4 Global Immunomodulators by Application
4.1 Immunomodulators Segment by Application
4.1.1 Residential
4.1.2 Commercial
4.2 Global Immunomodulators Sales by Application: 2015 VS 2021 VS 2027
4.3 Global Immunomodulators Historic Sales by Application (2015-2021)
4.4 Global Immunomodulators Forecasted Sales by Application (2021-2027)
4.5 Key Regions Immunomodulators Market Size by Application
4.5.1 North America Immunomodulators by Application
4.5.2 Europe Immunomodulators by Application
4.5.3 Asia-Pacific Immunomodulators by Application
4.5.4 Latin America Immunomodulators by Application
4.5.5 Middle East and Africa Immunomodulators by Application
5 North America Immunomodulators Market Size by Country (2015-2027)
5.1 North America Market Size Market Share by Country (2015-2021)
5.1.1 North America Immunomodulators Sales Market Share by Country (2015-2021)
5.1.2 North America Immunomodulators Revenue Market Share by Country (2015-2021)
5.2 North America Market Size Market Share by Country (2021-2027)
5.2.1 North America Immunomodulators Sales Market Share by Country (2021-2027)
5.2.2 North America Immunomodulators Revenue Market Share by Country (2021-2027)
5.3 North America Market Size By Growth by Country
5.3.1 U.S. Immunomodulators Market Size By Growth (2015-2027)
5.3.2 Canada Immunomodulators Market Size By Growth (2015-2027)
6 Europe Immunomodulators Market Size by Country (2015-2027)
6.1 Europe Market Size Market Share by Country (2015-2021)
6.1.1 Europe Immunomodulators Sales Market Share by Country (2015-2021)
6.1.2 Europe Immunomodulators Revenue Market Share by Country (2015-2021)
6.2 Europe Market Size Market Share by Country (2021-2027)
6.2.1 Europe Immunomodulators Sales Market Share by Country (2021-2027)
6.2.2 Europe Immunomodulators Revenue Market Share by Country (2021-2027)
6.3 Europe Market Size By Growth by Country
6.3.1 Germany Immunomodulators Market Size By Growth (2015-2027)
6.3.2 France Immunomodulators Market Size By Growth (2015-2027)
6.3.3 U.K. Immunomodulators Market Size By Growth (2015-2027)
6.3.4 Italy Immunomodulators Market Size By Growth (2015-2027)
6.3.5 Russia Immunomodulators Market Size By Growth (2015-2027)
7 Asia-Pacific Immunomodulators Market Size by Country (2015-2027)
7.1 Asia-Pacific Market Size Market Share by Country (2015-2021)
7.1.1 Asia-Pacific Immunomodulators Sales Market Share by Country (2015-2021)
7.1.2 Asia-Pacific Immunomodulators Revenue Market Share by Country (2015-2021)
7.2 Asia-Pacific Market Size Market Share by Country (2021-2027)
7.2.1 Asia-Pacific Immunomodulators Sales Market Share by Country (2021-2027)
7.2.2 Asia-Pacific Immunomodulators Revenue Market Share by Country (2021-2027)
7.3 Asia-Pacific Market Size By Growth by Country
7.3.1 China Immunomodulators Market Size By Growth (2015-2027)
7.3.2 Japan Immunomodulators Market Size By Growth (2015-2027)
7.3.3 South Korea Immunomodulators Market Size By Growth (2015-2027)
7.3.4 India Immunomodulators Market Size By Growth (2015-2027)
7.3.5 Australia Immunomodulators Market Size By Growth (2015-2027)
7.3.6 Taiwan Immunomodulators Market Size By Growth (2015-2027)
7.3.7 Indonesia Immunomodulators Market Size By Growth (2015-2027)
7.3.8 Thailand Immunomodulators Market Size By Growth (2015-2027)
7.3.9 Malaysia Immunomodulators Market Size By Growth (2015-2027)
7.3.10 Philippines Immunomodulators Market Size By Growth (2015-2027)
Continue…
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune -411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245